Member Info for JimiHendrix

CYP2C19 POC will very likely be used where labs are too slow, which is roughly 30-40% of the total UK market. NICE don’t have any new info, they’re waiting for NHSE. I’d like to think they’ll get the guide and toolkit out soon, which is expected to be very positive and supportive towards POC.

Even when they’re EBITDA positive they’ll still likely want to raise more funds for further product development.

Without DN’s vote, the resolutions would have passed. From my understanding he has been buying since the Covid test era so likely well under water, until recently where he was able to average down significantly.

Up to £1m to me sounds like a facility that the company will draw down from as and when it needs to. Do we know how much FDA submission costs? I’m also conscious that even with the rejected huge placing they still said they will likely need to raise again mid 2026.

This loan discussion must have happened after he increased to 16% due to insider trading rules, I would have thought.

Yes, also there’s a chance it’ll keep them funded until March, with plenty of news due by then.

Unfortunately not, they don’t have any more shares to issue. They’d need to call the meeting for permission to a lot more shares.

…oops pressed post accidentally. Yes, as I was saying I think UK and eventually SA will be their biggest markets. Any decent uptake in Europe will probably take years once they’ve gone through in-country validations. The US market is very tricky by the looks of it though I’m sure FDA approval next summer will boost the share price.

I’m not expecting much from CYP2C19 FDA approval to be honest. Genomadix have had this for years and have seen very little adoption with their test. I think the UK will give them the

I expected him to be a lot higher than thus by now. It means the buying pressure we’ve seen over the past few weeks was not him.

Also I’m thinking if he was involved in a new funding agreement then he would not have been able to buy on the open market yesterday when the threshold was crossed, as he’d be privy to insider info.

I do wonder whether the company will simply offer a new funding but at less discount / dilution to before, perhaps 0.4 - 0.6p. Particularly so as the Allenby clients who took part in the 400m have had a good chance to triple their money already. They could sell now and then take part in another placing.

I’d expect income from this pilot study, could extend the cash runway several months.

Great summary, Stephen.

I expect further news to follow soon, when Saudi Arabia decides something is a national priority, rollout can be faster than the UK, largely because health procurement and policy are more centralised (MOH/NUPCO/SFDA).

Vision 2030 push: Precision medicine and screening have explicit national backing (e.g., Saudi Genome Program, expansion of national newborn screening). When aligned with Vision 2030 deliverables, ministries have latitude to mobilise quickly.

Yes, the company will receive some decent income for the pilot. Saudi’s move fast too with new medical technology, it’ll be adopted nationally much quicker than we’ve seen in England and even Scotland.

Live births in Saudi Arabia approx 546k/yr. Assume 8–12% NICU admissions 44k–66k NICU babies/yr.

If 50–80% of NICU admissions are candidates for empiric aminoglycosides, annual testable cohort is 22k–53k.

Revenue sketch @ £100/kit: ~£2.2m–£5.3m/yr.

This is pretty incredible considering current market. With national rollout in Scotland happening right now as well, plus on the verge of UK adoption of CYP2C19 things are really starting to happen.

DG59 (final): “Starting antiplatelet treatment should not be delayed while waiting for test results… consider POC as an alternative if lab testing isn’t feasible at scale or while capacity is built.”

NICE evidence pack: notes POC gives results in ~1 hour, whereas lab testing of ~1 week risks missing results before discharge. That frames timeliness as clinically material even without a formal target. 

GLH feedback to NICE (consultation): reported real-world lab TATs ranging 24–72 hours up to 1–2 weeks, underscoring why POC may be needed for rapid decisions. 

Stroke guideline (RCP 2023): recommends DAPT within 24 hours for TIA/minor stroke, which is the clinical driver behind wanting genotype results quickly. (NICE references these stroke-care timelines in DG59.) 

East Genomics implementation guidance (Jan 2025): reminds clinicians that lab TATs may be longer than POC, so services must plan accordingly.

Zeeco, the NHS codeveloped this point of care test. To say they don’t care about turnaround times is pure silliness!

Genedrive should get all the HASUs and any region whose lab can’t meet the turnaround target. Approximately 40% of the market.

Converting in-the-money warrants to shares gives flexibility to sell into liquidity or hold if they like the outlook. The act of exercise itself is neutral on direction; it simply realises the warrant’s intrinsic value post-reset.

That said, removing the RiverFort warrant overhang is modestly cleaner for the cap table, which some investors read as a positive signal. The company confirmed the exercise exhausts RiverFort’s remaining facility warrants.

It’s neutral to positive.

And that’s 1000-5000% from what the share price was before the placing… around 1p ish.

I would imagine they’ll sell them on the next spike if not immediately when issued in a week or so. It’s a small amount so shouldn’t affect the share price, in fact it’ll help the market makers out as they’ve clearly been struggling to fill a large order(s).

If David N is reading, please can you confirm if you have crossed any 1% thresholds since your last update when you had reached 15% ? Many thanks!

The reason they’ve exercised is because the exercise price was reset to 0.2, the warrants put them immediately 150% in profit. Where as before the reset, their exercise price was at various prices between 10p and 45p so whilst they could have exercised earlier it would have made no economical sense and would have cost them a fortune and put them in immediate loss.

So even though they’re not worth much now it’s still a decent profit percentage and makes far more sense than had they exercised before the reset as they will have needed to wait for the share price to go up 1000 - 5000% before being in profit, lol.